Navamedic ASA (OSL:NAVA)
Norway · Delayed Price · Currency is NOK | Market Cap | 408.88M +9.2% |
| Revenue (ttm) | 571.24M +5.3% |
| Net Income | -16.20M |
| EPS | -0.79 |
| Shares Out | 23.98M |
| PE Ratio | n/a |
| Forward PE | 80.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,511 |
| Open | 16.50 |
| Previous Close | 17.05 |
| Day's Range | 16.50 - 16.95 |
| 52-Week Range | 16.65 - 27.90 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Navamedic ASA
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic... [Read more]
Financial Performance
In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.
Financial StatementsNews
Navamedic ASA Slides: Q1 2026
Navamedic ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Navamedic ASA Quarterly report: Q1 2026
Navamedic ASA has published its Q1 2026 quarterly earnings report on April 23, 2026.
Navamedic ASA (OSL:NAVA) Q1 2026 Earnings Report Preview: What To Expect
Navamedic ASA (OSL:NAVA) Q1 2026 Earnings Report Preview: What To Expect
Navamedic ASA Annual report: Q4 2025
Navamedic ASA has published its Q4 2025 annual report on February 12, 2026.
Navamedic ASA Earnings release: Q4 2025
Navamedic ASA released its Q4 2025 earnings on February 12, 2026, summarizing the period's financial results.
Navamedic ASA Slides: Q4 2025
Navamedic ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
Navamedic ASA (OSL:NAVA) Q4 2025 Earnings Report Preview: What To Look For
Navamedic ASA (OSL:NAVA) Q4 2025 Earnings Report Preview: What To Look For
Navamedic ASA Earnings release: Q3 2025
Navamedic ASA released its Q3 2025 earnings on October 28, 2025, summarizing the period's financial results.
Navamedic ASA Slides: Q3 2025
Navamedic ASA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.
Navamedic ASA Quarterly report: Q2 2025
Navamedic ASA has published its Q2 2025 quarterly earnings report on August 14, 2025.
Navamedic ASA Slides: Q2 2025
Navamedic ASA has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 14, 2025.
Navamedic ASA Transcript: M&A Announcement
The acquisition of dne Pharma's business for up to NOK 225 million expands product ownership in addiction treatment, with significant synergies and an expected EBITDA boost to NOK 25 million. Integration is straightforward, with most cost savings realized quickly.
Navamedic ASA Press release: M&A Announcement
Navamedic ASA issued a press release on June 24, 2025, disclosing material business information to investors.
Navamedic ASA Slides: M&A Announcement
Navamedic ASA has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2025.
Navamedic ASA Press release: M&A Announcement
Navamedic ASA issued a press release on June 24, 2025, disclosing material business information to investors.
Navamedic ASA Slides: M&A Announcement
Navamedic ASA has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2025.